Waldencast plc (WALD)
NASDAQ: WALD · Real-Time Price · USD
3.080
+0.560 (22.22%)
At close: Nov 21, 2025, 4:00 PM EST
2.990
-0.090 (-2.92%)
After-hours: Nov 21, 2025, 6:07 PM EST
Waldencast Revenue
In the year 2024, Waldencast had annual revenue of $273.87M with 25.55% growth. Waldencast had revenue of $142.29M in the half year ending December 31, 2024.
Revenue (ttm)
$273.87M
Revenue Growth
+25.55%
P/S Ratio
1.26
Revenue / Employee
$817,516
Employees
335
Market Cap
377.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 273.87M | 55.73M | 25.55% |
| Dec 31, 2023 | 218.14M | 52.01M | 31.30% |
| Dec 31, 2022 | 166.13M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Berkshire Hathaway | 372.13B |
| JPMorgan Chase & Co. | 167.23B |
| Bank of America | 101.45B |
| Wells Fargo & Company | 79.07B |
| Morgan Stanley | 68.53B |
| American Express Company | 65.29B |
| HSBC Holdings | 57.98B |
| The Goldman Sachs Group | 57.34B |
WALD News
- 7 days ago - Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting - GlobeNewsWire
- 9 days ago - Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities - GlobeNewsWire
- 11 days ago - Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates - GlobeNewsWire
- 6 weeks ago - Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum - GlobeNewsWire
- 2 months ago - Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand - GlobeNewsWire
- 3 months ago - Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation - GlobeNewsWire
- 3 months ago - Waldencast Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
- 4 months ago - Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand - GlobeNewsWire